The thiazolidinediones (rosiglitazone and pioglitazone) lower blood sugar levels among individuals with type II diabetes. The thiazolidinediones have favourable effects on surrogate markers of ...

Thiazolidinediones (TZDs) are the major drug class used to improve insulin sensitivity in the treatment of type 2 diabetes. However, TZDs have several adverse effects, including weight gain and ...

(Metformin also improves insulin sensitivity. See below.) Thiazolidinediones are taken once a day with or without food. Pioglitazone (Actos) is an example of a thiazolidinedione ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

sulfonylureas and thiazolidinediones. Semaglutide was associated with 40% to 70% reduced risks of a first-time Alzheimer’s diagnosis, especially against insulin and even compared to other GLP-1 ...

Rising demand for thiazolidinediones Based on drug class, the prediabetes market size from the thiazolidinediones segment is likely to accelerate at a robust pace between 2024 and 2032.

Researchers are investigating whether diabetes and eye disease drugs could also be used to treat or even prevent dementia.

These included: insulin, metformin, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas, thiazolidinediones and other GLP-1 ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs.

Geriatrics and Aging. 2008;11(3):179-183. Accumulating evidence from long-term trials has demonstrated the negative effects of the thiazolidinediones on cardiovascular disease among individuals ...